Thursday, March 31, 2016

BRIEF-Regeneron and Sanofi announce positive Dupilumab topline results from two Phase 3 trials in inadequately controlled moderate-to-severe atopic Dermatitis patients

* Regeneron And Sanofi announce positive Dupilumab

topline results from two Phase 3 trials in inadequately

controlled moderate to-severe atopic Dermatitis patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)